Eli Lilly (LLY) stock news

Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?

These stocks have been going in different directions over the past year, but that trend may not necessarily continue.

The FDA Ordered GLP-1 Vision-Loss Warnings For Some Products. Shares of Eli Lilly and Novo Nordisk Were Unfazed.

The updated labeling covers Mounjaro, Zepbound, Ozempic and Wegovy.

Jim Cramer Says Eli Lilly “Is a $2 Trillion Stock” as It Nears Tesla’s Market Cap

Key TakeawaysEli Lilly closed Friday worth $1. 27 trillion, about 10% short of Tesla’s value, after a week when Tesla and the AI trade sold off.

Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval

Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.

Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs

Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.

Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down

The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.

Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor

Key TakeawaysEli Lilly hit a record high on Friday after raising its 2026 revenue forecast to $91-$92 billion, lifting its market value to about $1. 1 trillion, level with Berkshire Hathaway.

Santoli: AI bull market almost surely needs tech stocks to recover to keep advancing

The road to bull-market glory does not run through Walmart and Berkshire Hathaway and Eli Lilly.

Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy?

The drugmaker continues its impressive run.

What Has Changed About Owning Eli Lilly Stock?

For questions about this article or underlying research, email help@trefis.com.

After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?

Eli Lilly stock is trading at a record high.

S&P 500, Nasdaq End Third Straight Week Lower As Investors Move Away From Tech, AI — AMZN, INTC, LLY, RBLX In Focus

The S&P 500 and Nasdaq 100 ended the week down 0.6% and 2%, respectively.

The big winners of the tech wreck are biopharma stocks

The shares of large drugmakers like Lilly, Gilead and J&J keep hitting record highs.

Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game

Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.

What Sent Eli Lilly Stock Higher?

For questions about this article or underlying research, email help@trefis.com.

Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock closed at a record high.

The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.

Stocks making the biggest moves midday: ADT, Alphabet, Caterpillar, Eli Lilly, Chipotle & more

These are the stocks posting the largest moves midday.

Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion

Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.

Walmart, Eli Lilly join growing pushback against OKX–ICE tokenized stock plans

Five more companies have objected, bringing the total to 38 as a rival Canton venue prepares to launch with an issuer-sponsored stock under the SEC's innovation exemption.

Stocks making the biggest moves premarket: Alphabet, Caterpillar, Eli Lilly, DoorDash & more

These are the stocks posting the largest moves in the premarket.

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

Court rejects Novo bid to block Lilly obesity drug ads

Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.

US judge won’t block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.

Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Here are Monday's biggest analyst calls: SpaceX, Nvidia, Apple, CoreWeave, Amazon, Meta, Eli Lilly & more

Here are the biggest calls on Wall Street on Monday.

HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion

What Was Eli Lilly Telling You Before Its Stock Ran?

An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the identical period would have yielded about $11,790. By mid-2026, two drugs,…

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine.

A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything

Eli Lilly spent most of its 150-year history as a quiet insulin maker before a single drug reshuffled the entire obesity market and turned a modest stake into a fortune that left the S&P 500 in the dust. The question now is whether the…

Novo Nordisk and Eli Lilly Just Got Some Fantastic News

A new government-funded study found that GLP-1 drugs slow the aging process in mice.

Eli Lilly’s weight-loss pill wins EU drug regulator’s backing

Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets

Shares of AbbVie, Eli Lilly and Gilead Sciences closed near record highs

Stock Market Today: Dow Jumps 450 Points As Yields Dive; Eli Lilly Charges Higher (Live Coverage)

The Dow Jones index rises Thursday while the Nasdaq slides on further tech weakness.